Quality of life and intrinsic capacity in patients with post-acute COVID-19 syndrome is in relation to frailty and resilience phenotypes.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 06 2023
Historique:
received: 13 08 2022
accepted: 03 02 2023
medline: 5 6 2023
pubmed: 3 6 2023
entrez: 2 6 2023
Statut: epublish

Résumé

The objective of this study was to characterize frailty and resilience in people evaluated for Post-Acute COVID-19 Syndrome (PACS), in relation to quality of life (QoL) and Intrinsic Capacity (IC). This cross-sectional, observational, study included consecutive people previously hospitalized for severe COVID-19 pneumonia attending Modena (Italy) PACS Clinic from July 2020 to April 2021. Four frailty-resilience phenotypes were built: "fit/resilient", "fit/non-resilient", "frail/resilient" and "frail/non-resilient". Frailty and resilience were defined according to frailty phenotype and Connor Davidson resilience scale (CD-RISC-25) respectively. Study outcomes were: QoL assessed by means of Symptoms Short form health survey (SF-36) and health-related quality of life (EQ-5D-5L) and IC by means of a dedicated questionnaire. Their predictors including frailty-resilience phenotypes were explored in logistic regressions. 232 patients were evaluated, median age was 58.0 years. PACS was diagnosed in 173 (74.6%) patients. Scarce resilience was documented in 114 (49.1%) and frailty in 72 (31.0%) individuals. Predictors for SF-36 score < 61.60 were the phenotypes "frail/non-resilient" (OR = 4.69, CI 2.08-10.55), "fit/non-resilient" (OR = 2.79, CI 1.00-7.73). Predictors for EQ-5D-5L < 89.7% were the phenotypes "frail/non-resilient" (OR = 5.93, CI 2.64-13.33) and "frail/resilient" (OR = 5.66, CI 1.93-16.54). Predictors of impaired IC (below the mean score value) were "frail/non-resilient" (OR = 7.39, CI 3.20-17.07), and "fit/non-resilient" (OR = 4.34, CI 2.16-8.71) phenotypes. Resilience and frailty phenotypes may have a different impact on wellness and QoL and may be evaluated in people with PACS to identify vulnerable individuals that require suitable interventions.

Identifiants

pubmed: 37268716
doi: 10.1038/s41598-023-29408-z
pii: 10.1038/s41598-023-29408-z
pmc: PMC10235830
doi:

Types de publication

Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8956

Informations de copyright

© 2023. The Author(s).

Références

J Gerontol A Biol Sci Med Sci. 2018 Nov 10;73(12):1653-1660
pubmed: 29408961
Qual Life Res. 2016 May;25(5):1313-21
pubmed: 26482825
Ageing Res Rev. 2022 Nov;81:101686
pubmed: 35820609
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
BMJ. 2021 Mar 31;372:n693
pubmed: 33789877
Pharmacoeconomics. 2000 Jan;17(1):13-35
pubmed: 10747763
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
N Engl J Med. 2020 May 21;382(21):1973-1975
pubmed: 32202721
Clin Rev Allergy Immunol. 2023 Feb;64(1):66-74
pubmed: 33609255
J Am Geriatr Soc. 2018 Jul;66(7):1276-1283
pubmed: 29684237
Ann Intern Med. 2021 May;174(5):723-725
pubmed: 33284676
Depress Anxiety. 2003;18(2):76-82
pubmed: 12964174
J Nutr Health Aging. 2020;24(7):692-695
pubmed: 32744562
Lancet. 1999 Jan 16;353(9148):205-6
pubmed: 9923878
Int J Infect Dis. 2022 Dec;125:287-293
pubmed: 36191820
J Gerontol A Biol Sci Med Sci. 2016 Apr;71(4):489-95
pubmed: 26718984
BMC Med. 2020 Nov 10;18(1):355
pubmed: 33167965
Qual Life Res. 2021 Dec;30(12):3367-3381
pubmed: 34146226
J Med Virol. 2021 Apr;93(4):2453-2460
pubmed: 33377529
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Age Ageing. 2021 May 5;50(3):631-640
pubmed: 33951156
Int J Environ Res Public Health. 2021 Mar 05;18(5):
pubmed: 33807869
Thorax. 2021 Apr;76(4):396-398
pubmed: 33172844
Thorax. 2021 Apr;76(4):405-407
pubmed: 33273028
Arch Gerontol Geriatr. 2020 Jan - Feb;86:103939
pubmed: 31525556
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Transl Res. 2022 Mar;241:96-108
pubmed: 34695606
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
PLoS One. 2021 Aug 5;16(8):e0255427
pubmed: 34351975
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
J Am Med Dir Assoc. 2013 Jun;14(6):392-7
pubmed: 23764209
Respir Med. 2021 Jan;176:106272
pubmed: 33302142
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026

Auteurs

Giovanni Guaraldi (G)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Largo del Pozzo, 71, 41124, Modena, Italy. giovanni.guaraldi@unimore.it.
Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy. giovanni.guaraldi@unimore.it.

Jovana Milic (J)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Largo del Pozzo, 71, 41124, Modena, Italy.

Sara Barbieri (S)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Largo del Pozzo, 71, 41124, Modena, Italy.

Tommaso Marchiò (T)

University of Modena and Reggio Emilia, Modena, Italy.

Agnese Caselgrandi (A)

University of Modena and Reggio Emilia, Modena, Italy.

Federico Motta (F)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Largo del Pozzo, 71, 41124, Modena, Italy.

Bianca Beghè (B)

Respiratory Unit, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.
Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.

Alessia Verduri (A)

Respiratory Unit, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Michela Belli (M)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Largo del Pozzo, 71, 41124, Modena, Italy.

Licia Gozzi (L)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Vittorio Iadisernia (V)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Matteo Faltoni (M)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Giulia Burastero (G)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Andrea Dessilani (A)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Martina Del Monte (M)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Giovanni Dolci (G)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Erica Bacca (E)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Giacomo Franceschi (G)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Dina Yaacoub (D)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Sara Volpi (S)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Alice Mazzochi (A)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Enrico Clini (E)

Respiratory Unit, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.
Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.

Cristina Mussini (C)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Largo del Pozzo, 71, 41124, Modena, Italy.
Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH